The Latest Cardiac and Vascular News
MIAMI, Oct. 21, 2026 /PRNewswire/ — Resolve Therapeutics, LLC, a clinical-stage biotechnology company developing nuclease-Fc fusion proteins designed to degrade pathogenic extracellular nucleic acids, today announced two e-posters featuring preclinical data on its RNase-Fc fusion protein…
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) — Precision Neuroscience Corporation (Precision), a brain–computer interface (BCI) company, today announced that Konstantinos Alataris, Ph.D., founder and former chief executive officer of Nevro, has joined as president, and Katherine Neuenfeldt, who led the U.S. launch and market access strategy for Nevro’s Senza spinal cord stimulation system, has joined as senior vice president, commercial strategies. Following Precision’s $250 million Series D financing, the two executives will advance the company’s BCI toward commercialization, drawing on their experience developing, launching, and securing reimbursement for implantable medical devices. “Precision has established a leading position in BCI technology, and our recent financing gives us the resources to take the next step,” said Michael Mager, co-founder and CEO of Precision. “Bringing a new Class III medical device to market takes more than technical skill and capital. We have to be able to build products that physicians can rely on and that insurers will pay for. Konstantinos and Katherine have done exactly that with implantable devices in the nervous system. Their experience will be critical as we move from demonstrating what our technology can do to making it available to patients.” Alataris has served on Precision’s board of directors since May 2025 and will continue in that role alongside his responsibilities as president. Alataris founded Nevro in 2006 and led the development and commercial launch of its high-frequency spinal cord stimulation technology for chronic pain. Nevro received European CE marking for its spinal cord stimulation system in 2010, went public on the New York Stock Exchange in 2014, and received FDA approval for the system in 2015, achieving a multi-billion dollar market capitalization. Beyond Nevro, Alataris has held executive and board roles across medical device, biotechnology, and pharmaceutical companies, including serving as president and CEO of Zosano Pharma, co-founding Nēsos, and chairing the scientific advisory board of Iota Biosciences until its acquisition by Astellas Pharma. He currently serves on the boards of Oryzon Genomics SA (BME: ORY), a clinical-stage biopharmaceutical company developing epigenetic therapies for cancer and central nervous system (CNS) disorders, and Delsona Therapeutics, a Columbia University spinout developing focused ultrasound therapeutics. He is also a partner and co-chairman at Forepont Capital, a New York-based private equity firm. Previously, he was a vice president at healthcare investment firm Bay City Capital. “Precision has demonstrated that it is possible to achieve high-performance neural control without penetrating the brain — something many believed couldn’t be done. That is a testament to the vision and dedication of co-founders Michael Mager and Ben Rapoport and the entire team,” Alataris said. “The next chapter is turning today’s breakthroughs into everyday medicine: reliable, repeatable, exceptional performance that neurosurgeons and patients can depend on, case after case. That is the work I wanted to help lead. Moving from the board into an operating role was a natural progression, an opportunity to roll up my sleeves and help bring the promise of Precision’s technology to patients.” Neuenfeldt leads Precision’s commercial strategy and market access efforts. She joined Nevro when the company had roughly 60 employees and led marketing for its successful 2015 U.S. launch of HF10 therapy. Later, as vice president of market access, she built and led a 40-person commercial team spanning national accounts, pricing and contracting, analytics, patient access, and reimbursement. Her team drove insurance coverage, adoption, and market differentiation for Nevro’s products globally. She previously spent six years at Medtronic Cardiovascular, where she led the U.S. launch of its flagship Endurant AAA stent graft, and most recently served as senior vice president of commercial strategies at Presidio Medical. “Joining Precision allows me to bring my experience launching disruptive medical devices backed by rigorous clinical evidence to a mission that is deeply personal to me,” Neuenfeldt said. “A device can be safe and effective, and a physician can want to use it, but if payers don’t cover it, patients won’t have access. For BCI technologies to reach people living with ALS, spinal cord injury, and brainstem stroke, we need to lay the groundwork for insurance coverage now, including generating clinical evidence that demonstrates meaningful benefits for patients.” The appointments follow Precision’s $250 million Series D financing, which brought its total capital raised to $430 million. Since its founding in 2021, Precision has built the largest clinical footprint in BCI, with more than 100 patient procedures across 18 medical institutions. The company has demonstrated high-resolution neural recording across 4,096 electrodes and real-time decoding of intended movement, received FDA clearance for its Layer 7™ cortical surface array, and published peer-reviewed research, including in Nature Biomedical Engineering. It has also established a commercial partnership with Medtronic and built a wholly owned MEMS manufacturing facility in Texas. About Precision NeurosciencePrecision Neuroscience is developing breakthrough treatments and technology for millions of people worldwide. The company is building the only brain–computer interface designed to be minimally invasive, safely removable, and high-bandwidth. To learn more about how Precision is connecting human and artificial intelligence, visit www.precisionneuro.io. Media Contactmedia@precisionneuro.io
HOUSTON–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) has accepted XCath’s Iris Surgical Robotic System into its Total Product Life Cycle Advisory Program (TAP) Pilot, the company announced today. The system is intended for remote robotic-assisted mechanical thrombectomy in patients with acute ischemic stroke. XCath is a medical device company advancing endovascular surgical robotics, and the FDA’s decision comes after it granted Breakthrough Device Designation to the Iris Syste
DALLAS–(BUSINESS WIRE)–NeuWire Medical today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for STROKE-REWIRE, a pivotal study evaluating the ReWire Vagus Nerve Stimulation System in patients with chronic ischemic stroke and upper-limb dysfunction. The prospective, multicenter, randomized, sham-controlled study will enroll up to 135 participants across up to 12 U.S. clinical sites. Study initiation is expected in t
IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) — Balt announced today it has enrolled the first patients in North America in the premarket approval (PMA) clinical trial, PIONEER (PIvotal Study Of the Silk Vista Baby Flow Diverters iN the TrEatmEnt of Unruptured Intracranial AneuRysms). Pioneer is the first prospective trial exclusively assessing the role of flow diversion in the treatment of aneurysms in distal small arteries in the brain. This landmark trial is actively enrolling at hospitals in both the U.S. and Canada and is the U.S. approval study for the Silk Vista Baby flow diverter. Co-Primary Investigator, Vitor Mendes-Pereira, M.D., MSc (St. Michael’s Hospital, Toronto, Canada) stated, “The Silk Vista Baby has been a paradigm shift in the care of neurovascular patients. It provides physicians with a significant improvement on access to distal aneurysms with a low profile microcatheter over the treatment options we have available and enables us to provide better care for more patients.” The Silk Vista Baby device was the first flow diverter in the world that delivers through a small 0.017-inch diameter microcatheter. Obtaining European Union regulatory approval in 2018, the device has been used to treat thousands of aneurysm patients around the world and studied extensively in several clinical studies. Patients with distal brain aneurysms often have those aneurysms arise off very small blood vessels and the endovascular treatment options often require access devices that are too big, or the anatomy is not suitable for open surgical solutions. “The PIONEER study is an important advance for the care of aneurysm patients in the U.S.,” said co-Primary Investigator, Ricardo Hanel, M.D., PhD (Baptist Medical Center, Jacksonville, FL), “This study will add tremendously to our knowledge of how to care for patients with distal aneurysms and potentially brings another life-saving tool to the patients of the United States. One that has already changed care for much of the rest of the world.” Balt CEO Pascal Girin commented, “PIONEER marks the second PMA trial for Balt, following the groundbreaking STEM study which resulted in the PMA approval of the SquidTM Liquid Embolic for chronic subdural hematoma patients. We are currently working on multiple additional PMA studies and are committed to continue bringing Balt’s innovative solutions to novel indications for physicians and patients around the world.” About Balt: Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular diseases such as ischemic strokes, aneurysms and other hemorrhagic conditions including arteriovenous malformations, dural arteriovenous fistulas and chronic subdural hematomas. A pioneer in the neurovascular field, Balt designs, manufactures and distributes the broadest portfolio of products in the neurovascular space and is now focused on expanding its geographic presence in the U.S. Visit Balt at https://www.baltgroup.com/ ContactGreg ChodaczekGilmartin Groupgreg@gilmartinir.com
Proposed acquisition would add NeoCast™, an investigational technology designed for controlled delivery and predictable distal penetration, to Terumo Neuro’s neurovascular portfolio.
NeoCast
The next-generation in liquid embolics
Aliso Viejo, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) — Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH) Proposed acquisition would add NeoCast™, an investigational technology designed for controlled delivery and predictable distal penetration, to Terumo Neuro’s neurovascular portfolio. Aliso Viejo, Calif. – September 29, 2026 – Terumo Neuro today announced that it has signed an agreement to acquire Arsenal Medical Inc., a privately held, clinical-stage biomaterials company developing NeoCast™, an investigational next-generation liquid embolic technology for the treatment of chronic subdural hematoma (cSDH). Upon completion, the proposed acquisition would expand Terumo Neuro’s liquid embolic portfolio, advance its strategy to bring differentiated neurovascular technologies to physicians and patients, and support its continued focus on innovations to preserve and restore brain health. “NeoCast represents a compelling opportunity to advance what could be a game-changing innovation in the treatment of chronic subdural hematoma,” said Carsten Schroeder, CEO, Terumo Neuro. “As MMA embolization emerges as an important new treatment option, this purpose-developed, next-generation liquid embolic technology has the potential to make a meaningful impact for physicians and patients, while supporting our mission to preserve and restore brain health. We are impressed by the progress Arsenal Medical has made and look forward to combining our global neurovascular expertise with its differentiated technology platform following the close of the transaction.” cSDH is a significant and growing neurological condition, particularly among aging populations. The condition may cause cognitive decline and disability, has been described as a potential cause of reversible dementia, and can be associated with substantial mortality within one year. While surgical drainage remains a common treatment approach, recurrence after surgery continues to be a clinical challenge. Middle meningeal artery embolization has emerged as a promising adjunctive or alternative approach by targeting the vascular pathology believed to contribute to hematoma persistence and recurrence.1,2,3 Arsenal Medical has developed NeoCast, a next-generation, solvent-free, non-adhesive biomaterial intended for embolization of the middle meningeal artery (MMA). It is engineered for controlled delivery and predictable distal penetration, without solvents or adhesives associated with many embolic devices. Arsenal Medical has advanced NeoCast through first-in-human clinical experience in cSDH and recently received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for RADIANT, a pivotal randomized, multicenter study evaluating NeoCast adjunctively with surgery for symptomatic subacute and chronic subdural hematoma.4 The first patients have been enrolled in RADIANT. Final results from the EMBO-02 first-in-human study showed that NeoCast met its primary feasibility and safety endpoints, with 96% of subjects achieving at least 50% hematoma volume reduction and 75% achieving complete hematoma resolution at final follow-up. Notably, 79% of 24 patients were treated with embolization alone, and 10 subjects were treated without general anesthesia.4 The study also reported functional outcome improvements, with 79% of patients demonstrating better functional status based on mRS and quality-of-life measures compared with baseline through 180 days. These findings are preliminary and provide supporting clinical context as NeoCast advances into RADIANT, a prospective, randomized, multicenter pivotal study comparing NeoCast to Onyx LES for the treatment of symptomatic subacute and chronic subdural hematoma adjunctively with surgery.5,6 “Arsenal Medical was founded on the idea that advanced materials can transform the way challenging medical conditions are treated,” said Upma Sharma, PhD, President and CEO, Arsenal Medical. “NeoCast is a powerful example of that vision. It was designed to provide physicians with controlled delivery and consistent distal penetration without the use of solvents or adhesives. Terumo Neuro’s leadership in neurovascular innovation makes it the ideal organization to help realize the full potential of NeoCast through its next stage of development following the close of the transaction.” NeoCast is an investigational device and is not approved for commercial sale in the United States. The proposed transaction is subject to customary closing conditions. Financial terms of the agreement were not disclosed. For more information, contact:Rebecca Janzon, Terumo Neuro, Global Director Corporate CommunicationsEmail: Rebecca.janzon@microvention.com About Terumo NeuroTerumo Neuro is on a mission to preserve and restore brain health by advancing innovation that changes what’s possible in neurovascular care. Working shoulder to shoulder with physicians, customers, and Associates, we turn deep clinical insight into proven, refined solutions that elevate practice and improve patient outcomes — the kind of game-changing impact that redefines neuro-endovascular treatment. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers a comprehensive portfolio for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, our products are sold in more than 70 countries.For more information, please visit www.terumoneuro.com. About Terumo CorporationTerumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. About Arsenal MedicalArsenal Medical is a privately-held, venture-backed, clinical-stage company developing innovative biomaterials to address challenging and underserved medical problems. Its lead product targets neurovascular conditions. The company was founded by academic luminaries Robert Langer and George Whitesides, together with entrepreneur investor Carmichael Roberts, who shared a vision for how materials can transform medical devices. Learn more at www.arsenalmedical.com. References Levitt MR, Hirsch JA, Chen M. Middle meningeal artery embolization for chronic subdural hematoma: an effective treatment with a bright future. J Neurointerv Surg. 2024 Mar 14Shankar JJS, Alcock S, Kashani N, et al.; EMMA-Can investigators. Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery: The EMMA-Can Randomized Clinical Trial. JAMA. Published online April 30, 2026Mascitelli Justin R, et al.; Current state of the field and recommendations for middle meningeal artery embolization in chronic subdural hematoma: A Report of the SNIS Standards and Guidelines Committee, Endorsed by ANZSNR and ESMINT. Journal of NeuroInterventional Surgery, April 2026Next-generation liquid embolic leads to “substantial” cSDH resolution and functional outcome gains. NeuroNews, July 24, 2026Arsenal Medical. Treatment with NeoCast, a Next-Generation Liquid Embolic, Results in Substantial Chronic Subdural Hematoma Resolution and Functional Outcome Gains in Final EMBO-02 First-in-Human Results. Press announcement issued July 22, 2026U.S. Food and Drug Administration. PMA Supplement Approval Letter: Onyx Liquid Embolic System (LES), P030004/S035. December 8, 2025 Contact Info Rebecca Janzonrebecca.janzon@microvention.com+1 949-685-4391
Attachments
Terumo Neuro Acquires Arsenal Medical
NeoCast
Expands Company’s Portfolio of Advanced Neurovascular Catheters to Support Treatment in Smaller and More Distal Anatomies WEST JORDAN, Utah, Sept. 28, 2026 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced U.S. Food and Drug Administration 510(k) clearance for the FreeClimb® 46 catheter with Tenzing® 4. The two components are engineered as an integrated system to provide neurovascular access. FreeClimb® 46 and Tenzing® 4 are the newest offerings in Route 92’s portfolio of advanced neurovascular catheters. The FreeClimb 46 system joins FreeClimb 54, 70 and 88, and complements the HiPoint® 70 and HiPoint 88 systems, which also feature the company’s proprietary Monopoint® single-operator system. All Route 92 access and aspiration catheters are powered by custom-sized Tenzing delivery catheters. The navigational capabilities of Tenzing enable atraumatic, precise, and controlled access through neurovascular anatomy, establishing stable access for the treatment of complex neurovascular diseases. “In neurovascular intervention, access is critical,” said Matthew D. Alexander, M.D., Medical Director of Neurointerventional Radiology at Sutter Medical Center in Sacramento, California. “Tenzing supports consistent navigation through even the most challenging cases, allowing us to reach the anatomy we need to treat. The FreeClimb 46 with Tenzing 4 expands Route 92’s catheter technologies to smaller and more distal vessels, where the clinical need is large and accurate delivery is critical to achieving the best outcomes for my patients. I look forward to bringing this next level of neurovascular access into my practice.” The FreeClimb 46 catheter system, including Tenzing 4, and all Route 92 catheters and systems are covered by a portfolio of more than 200 issued patents in the U.S. and international jurisdictions.About Route 92 Medical, Inc.Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering, innovative product design and revolutionary procedural change. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn. CONTACT: Contacts:
For media:
Gwen Gordon
Gwen@gwengordonpr.com
Enrollment completed in the double-blind, placebo-controlled Phase 4 study (NCT05955326) of sovateltide (Tycamzzi®), with final study data expected in Q1 2027Five sovateltide abstracts accepted at World Stroke Congress, October 21-23, 2026, Seoul, South Korea, including an interim analysis of the Phase 4 trialGlobal Phase 3 RESPECT-ETB trial (NCT05691244) actively enrolling and remains on track for topline data in early 2028 WILLOWBROOK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) — Pharmazz, Inc. (“Pharmazz” or the “Company”), a biopharmaceutical company developing novel therapeutics for critical care and neurovascular conditions, today announced that enrollment is complete in its 160-patient Phase 4 clinical study of sovateltide (Tycamzzi®) in patients with acute cerebral ischemic stroke in India. The Phase 4 study (NCT05955326) is a post-approval commitment required by Indian regulators. The double-blind, placebo-controlled trial utilizes the same sovateltide dosing regimen, randomization, and 24-hour treatment window as the global Phase 3 RESPECT-ETB trial, and the same protocol and eligibility criteria as the Phase 3 study that supported approval in India. The primary endpoint is the proportion of patients with adverse events and serious adverse events. Key secondary endpoints measure Day 90 neurological recovery, functional independence, and disability using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), and the Barthel Index. Final data are expected in Q1 2027. Pharmazz conducted a prespecified interim analysis in September 2025, when the first 80 patients reached the Day 90 endpoint, and presented those results at the International Stroke Conference 2026 in New Orleans. In that analysis, 92% of sovateltide-treated patients achieved an mRS score of 0 to 2 at Day 90, compared with 58% in the control arm (p=0.0004889). No drug-related adverse events were observed. “Dosing the final patient in our Phase 4 study marks an important milestone in our mission to address severe neurovascular conditions with high unmet medical needs,” said Dr. Anil Gulati, M.D., Ph.D., Chairman and Chief Executive Officer of Pharmazz, Inc. “Acute ischemic stroke remains a leading cause of long-term disability worldwide, and treatment options are limited. The fact that Sovateltide has been used to treat more than 140,000 patients in India since launch provides empirical real-world evidence that the selective endothelin B receptor agonist is able to promote neurogenesis, angiogenesis, and neuronal survival. We are actively enrolling in our global Phase 3 RESPECT-ETB trial and look forward to reporting final data in early 2028.” Upcoming Presentations at the 18th World Stroke Congress Five presentations will be made on-site at the upcoming 18th World Stroke Congress, taking place October 21-23, 2026, at the Convention & Exhibition Center, Seoul, South Korea. A meta-analysis assessing the effectiveness and safety of sovateltide in patients with acute ischemic strokeA global Phase III trial (RESPECT-ETB) to evaluate safety and effectiveness of sovateltide (Tycamzzi®) in ACIS patients Effect of sovateltide (Tycamzzi®) on the thrombolytic activity of alteplase and tenecteplaseAn interim analysis of multicentric, randomized Phase 4 clinical trial of sovateltide (Tycamzzi®) in AIS patients The development of sovateltide for cerebral ischemic stroke patients. About Sovateltide Sovateltide (IRL-1620) is a first-in-class endothelin-B receptor agonist that promotes neurogenesis, angiogenesis, and neuronal survival following acute hypoxic and ischemic insults. The drug is currently being evaluated in clinical programs for acute ischemic conditions. The Phase 3 RESPECT-ETB (ClinicalTrials.gov ID: NCT05691244) trial is being conducted at 57 sites in the US, Germany, Spain, and the UK, and is designed to enroll 514 stroke patients. In September 2026, the U.S. FDA granted Orphan Drug Designation to sovateltide for the treatment of neonatal hypoxic-ischemic encephalopathy. About Orphan Drug Designation The FDA’s Orphan Drug Designation program provides orphan status to investigational drugs and biological products intended to safely and effectively treat, diagnose, or prevent rare diseases or disorders that affect fewer than 200,000 people in the United States. The designation qualifies the sponsor for specific development incentives under the Orphan Drug Act, which may include tax credits for qualified clinical testing, exemptions from prescription drug user fees (PDUFA), and potential eligibility for seven years of market exclusivity in the U.S. upon regulatory approval for the designated indication. About Pharmazz, Inc. Pharmazz, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class therapies for critical care medicine. For more information, please visit www.pharmazz.com. Disclaimer: Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors David Costello MediaShruti Gulati Tel+1 630 780 6087 Tel+1 630 780 6087E maildavid.costello@pharmazz.com E mailshruti.gulati@pharmazz.com
LVOne is the only blood-based diagnostics kit for stroke diagnosis to be CE certifiedCAMBRIDGE, United Kingdom, Sept. 16, 2026 (GLOBE NEWSWIRE) — UpFront Diagnostics has announced CE mark approval for LVOne—the world’s first rapid blood test to diagnose stroke, and the first device of its kind to achieve this certification. The approval confirms that LVOne meets all EU safety, health, and environmental standards, enabling UpFront to launch the device across the region and bring advanced diagnostic technology to millions of new patients and providers throughout Europe. This marks the first time a blood test-based stroke diagnostic in-vitro-diagnosis test device has received CE mark approval. Effective stroke triage requires portable, affordable tools that operate wherever the patient is, rather than bulky equipment confined to radiology suites. LVOne bridges this gap, extending rapid stroke detection beyond well-resourced specialist centres directly to emergency teams and paramedics in the field. By shrinking the time between first contact and thrombectomy, LVOne ensures patients reach specialised treatment faster, regardless of location or which ambulance responds. “Stroke is a leading cause of death worldwide,” said Gonzalo Ladreda, CEO and Co-founder of UpFront Diagnostics. “The LVOne test democratises access to early stroke diagnosis, and securing CE mark approval marks a major regulatory milestone that accelerates our mission to reduce diagnostic times. We invite acute and emergency care providers across the EU to take advantage of this development as we enter a phase of rapid growth.” “Nine years ago, we began searching for stroke biomarkers in a field that had never delivered a patient-ready product,” said Dr Edoardo Gaude, Chief Scientific Officer and Co-founder. “LVOne transforms that research into a certified tool that identifies LVO stroke before a patient reaches hospital. We are excited to launch in Europe, integrating with existing pre-hospital pathways so every patient receives the best available care, wherever their stroke occurs.” LVOne places this capability directly into the hands of paramedics and emergency teams making split-second decisions in the field.It uses biomarkers for stroke detection, delivering objective results earlier than traditional assessments. LVOne, is UKCA marked, enabling real-world clinical deployment in the United Kingdom, and is currently being piloted in partnership with the London Ambulance Service. The company holds an ISO 13485:2016 certification for the design, development, manufacturing, and distribution of LVOne. About Upfront Diagnostics: Founded in Cambridge in 2017, Upfront Diagnostics is a medtech company focused on developing and commercialising rapid Point-of-care diagnostic tests for time-critical medical conditions. The company’s flagship product, LVOne, is a blood-based diagnostic test designed to support the early identification of severe stroke. Using innovative biomarkers, Upfront Diagnostics is enabling emergency teams to rapidly assess patients and identify those most likely to benefit from specialist interventions. For further information: Ritesh S, Communications & Marketing Specialist Upfront Diagnosticsritesh@upfrontdiagnostics.com
Company expands its neurovascular portfolio and broadens its offering for stroke intervention Engineered performance supports aspiration in complex anatomy Marks the second product to feature its proprietary Q’Apel Laser Cut Tube (QLCT™) technology FREMONT, Calif., Sept. 9, 2026…
